Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
Portfolio Pulse from Benzinga Newsdesk
UBS released a note stating that the ACIP Working Group recommends a universal RSV vaccine for individuals aged 75 and older from GSK. However, there is no endorsement for ages 50-59 due to limited data, and the recommendation for ages 60-74 is only for those 'at risk'.
June 26, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The ACIP Working Group recommends GSK's RSV vaccine for individuals aged 75 and older. However, there is no endorsement for ages 50-59 due to limited data, and the recommendation for ages 60-74 is only for those 'at risk'.
The recommendation for the 75+ age group is a positive development for GSK, potentially increasing vaccine sales. However, the lack of endorsement for the 50-59 age group and limited recommendation for the 60-74 age group may temper the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100